NVAX at a glance
NOVAVAX INC (NVAX, SEC CIK 1000694) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as June 23, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), NOVAVAX INC (NVAX) reported revenue of $1.1 billion (up 64.7% from FY2024) and net income of $440.3 million. Diluted EPS was $2.58.
- As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding NOVAVAX INC (NVAX) shares worth $721.7 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.1B
- +64.7% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 29 funds
- $721.7M · −2 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: development and commercialization of vaccines using proprietary recombinant nanoparticle technology and Matrix-M™ adjuvant platform
- New emphasized partnerships: non-exclusive Matrix-M™ licenses to Pfizer (Jan 2026) and expanded Sanofi agreement for pandemic influenza and COVID-19 combination vaccines
- Strategic shift: transitioned COVID-19 Vaccine commercialization leadership to Sanofi in 2025; focus on partnerships and licensing over direct commercialization
- Notable quantitative metric: $0.4 billion remaining obligations under advance purchase agreements; recognized $575.7 million product sales from terminated Canada APA in 2025
- Noteworthy fact: WHO prequalified the R21/Matrix-M™ adjuvant malaria vaccine in Dec 2023 with rollout in 24 countries as of Feb 2026, marking major commercial expansion beyond COVID-19
Management Discussion & Analysis
- Revenue $1.12B in 2025, up $441.3M YoY, driven by $685M product sales (+$471.8M) and $438.4M licensing (-$30.5M)
- Operating expenses $670.7M in 2025 vs $931.1M in 2024; cost of sales 10.7% of product sales vs 95.1% in 2024; R&D $342.3M vs $391.2M; SG&A $157.5M vs $337.2M
- Net income $440.3M in 2025 vs net loss $187.5M in 2024; operating margin approx. 38.7% ($440.3M net income / $1.12B revenue) vs negative margin prior year
- Best segment: Product sales $685.0M, +221% YoY; Worst segment: Licensing, royalties, and other $438.4M, -6.5% YoY
- Cash $750.5M end 2025 vs $938.2M end 2024; Operating cash flow used $244.6M; Issued $225M convertible notes; No dividends or buybacks disclosed
- Guidance: Expect funding from Sanofi milestones, royalties, product sales, $330M Credit facility available; Risks include regulatory approval delays, APA cancellations (Australia), and capital raising challenges
Risk Factors
- Regulatory risk: Uncertainty in revenue recognition from licensing agreements under ASC 606 requiring judgment on variable consideration and revenue timing
- Macroeconomic threat: Exposure to fluctuating interest rates with 4.625% Convertible Senior Notes and variable term loans tied to Term SOFR plus 5.00%
- Operational risk: Reliance on third-party CMOs and CDMOs for vaccine component manufacturing and raw material procurement, creating supply chain timing and cost estimation challenges
- Competitive risk: Partnership with Pfizer for Matrix-M adjuvant potentially faces competition in infectious disease vaccines market including influenza-COVID-19 combos by Sanofi
- Financial risk: $330 million senior secured term loan facility maturing in 2031 with mandatory principal and interest repayment increasing leverage and cash flow obligations
AI summary of the NVAX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue $68.3M, down $2.1M YoY from $70.4M
- Product sales $25.7M, up $12.3M YoY, driven by supply sales
- Licensing revenue $42.6M, down $14.4M YoY, with Sanofi revenue down $29.5M
- Net loss $31.4M vs $202.4M YoY, R&D expense $52.4M vs $98.3M
- Cash, restricted cash and marketable securities $627.0M vs $750.5M at December 31; operating cash burn $199.5M through nine months
Risk Factors
- New financing risk: February 2026 Credit Agreement added $50.0 million funded debt at 8.7% interest, secured by substantially all assets
- Liquidity risk: Operating cash outflows reached $199.5 million for nine months, with cash and securities totaling $627.0 million
- Regulatory and compliance risk: Australia APA exposure includes up to $92.5 million refundable if updated vaccine approval and delivery deadlines are missed
- Operational risk: Reliance on Serum for COVID-19 vaccine co-formulation, filling, and finishing
- Revenue concentration risk: Sanofi licensing revenue declined to $18.8 million from $48.3 million year over year
AI summary of the NVAX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Novavax announced third-quarter financial results for the period ended September 30, 2026
- Full financial results and management commentary are contained in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q3 revenue $68.3M, down 3% YoY, while product sales rose 91% to $25.7M as licensing revenue declined
- Net loss narrowed to $31.4M from $202.4M, driven by R&D falling 47% to $52.4M and SG&A declining 25%
Item 8.01: Other Events
- Sanofi dosed the fifth Phase 3 patient in its EU influenza-COVID-19 combination vaccine trial
- Milestone triggers $125 million payment to Novavax under the Sanofi collaboration
Item EX-99.1: Item EX-99.1
- $125 million milestone earned as Sanofi initiates Phase 3 European trial of influenza-COVID-19 combination vaccine
- Trial evaluates Nuvaxovid with Sanofi’s high-dose flu vaccine in adults aged 60 and older
Item 7.01: Regulation FD Disclosure
- Novavax issued a press release on October 29, 2026, containing the company’s material disclosure
- Investors should review Exhibit 99.1 for the underlying announcement and its potential market impact
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release issued August 6, 2026; detailed results in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $57M, down 76% year over year, reflecting the absence of prior-year $202M milestone and Takeda amendment benefits
- Net loss $53M versus $107M net income, while cash, securities and restricted cash totaled $724M at June 30
AI summaries of NVAX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for NVAX
Don't miss the next NVAX filing
- Alerts as it files. A push when NVAX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut NVAX, by share count.
- Ask anything. An AI agent that reads every NVAX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| MOTT DAVID M | M | Jun 20, 2026 | 18,880 | - |
| Alton Gregg H | M | Jun 20, 2026 | 18,880 | - |
| MCGLYNN MARGARET G | M | Jun 20, 2026 | 18,880 | - |
| MOTT DAVID M | M | Jun 20, 2026 | 18,880 | - |
| MCGLYNN MARGARET G | M | Jun 20, 2026 | 18,880 | - |
| DOUGLAS RICHARD | M | Jun 20, 2026 | 18,880 | - |
| King Rachel K. | M | Jun 20, 2026 | 18,880 | - |
| DOUGLAS RICHARD | M | Jun 20, 2026 | 18,880 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $983.7M | $682.2M | $1.1B |
| Operating Income | -$566.5M | -$248.9M | $452.8M |
| Net Income | -$545.1M | -$187.5M | $440.3M |
| Op. Margin | -57.6% | -36.5% | 40.3% |
| Net Margin | -55.4% | -27.5% | 39.2% |
| Balance Sheet | |||
| Total Assets | $1.8B | $1.6B | $1.2B |
| Equity | -$716.9M | -$623.8M | -$127.8M |
| ROE | 76.0% | 30.1% | -344.7% |
| Per Share | |||
| EPS | $-5.41 | $-1.23 | $2.58 |
| Cash Flow | |||
| Operating CF | - | -$87.3M | -$244.6M |
Source: XBRL data in NOVAVAX INC (NVAX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate NVAX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 29 | $721.7M |
| Q2 2026 | 31 | $629.0M |
| Q1 2026 | 31 | $506.8M |
| Q4 2025 | 25 | $464.2M |
| Q3 2025 | 28 | $485.9M |
| Q2 2025 | 30 | $359.8M |
| Q1 2025 | 27 | $259.7M |
| Q4 2024 | 22 | $298.7M |
- BlackRock+1.65M (+12%)
- Two Sigma Investments+1.42M (+35%)
- Invesco Ltd+1.25M (+529%)
- Citadel Advisors LLC+1.09M (+64%)
- Franklin Resources+499.5K (+4677%)
- State Street Corp−2.91M (-25%)
- AQR Capital Management−745.1K (-83%)
- Millennium Management−706.5K (-40%)
- Renaissance Technologies LLC−458.6K (-91%)
- Vanguard Portfolio Management LLC−358.6K (-5%)
- FMR LLC (Fidelity)−608.9K
- Dimensional Fund Advisors−396.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 223 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
NVAX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| SC 13G | Aug 7, 2026 | - | - | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 8-K | Jun 23, 2026 | - | Analysis | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 8-K | May 6, 2026 | - | Analysis | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | Apr 30, 2026 | - | - | |
| 4 | Apr 28, 2026 | - | - | - |
| 4 | Apr 16, 2026 | - | - | - |
| 4 | Mar 12, 2026 | - | - | - |
| 4 | Mar 9, 2026 | - | - | - |
| 4 | Mar 9, 2026 | - | - | - |
| 4 | Mar 9, 2026 | - | - | - |
| 4 | Mar 9, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
NVAX SEC filings: frequently asked questions
Which institutions hold NVAX stock?
As of September 30, 2026, the largest NOVAVAX INC (NVAX) holders among the 13F filers tracked by SignalX were BlackRock ($168.6 million), State Street Corp ($95.4 million), Vanguard Portfolio Management LLC ($78.4 million), Vanguard Capital Management LLC ($78.2 million), D.E. Shaw & Co ($62.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was NVAX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), NOVAVAX INC (NVAX) reported revenue of $1.1 billion (up 64.7% from FY2024) and net income of $440.3 million. Diluted EPS was $2.58. The figures come from the XBRL data in the 10-K.
What are the main risks in NVAX's latest 10-K?
In the 10-K filed February 26, 2026, NOVAVAX INC (NVAX) flagged: Regulatory risk: Uncertainty in revenue recognition from licensing agreements under ASC 606 requiring judgment on variable consideration and revenue timing. Macroeconomic threat: Exposure to fluctuating interest rates with 4.625% Convertible Senior Notes and variable term loans tied to Term SOFR plus 5.00%. (AI summary of the Risk Factors section.)
What did NVAX report in its latest 8-K?
NOVAVAX INC (NVAX) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Novavax announced third-quarter financial results for the period ended September 30, 2026.
What are the latest NVAX SEC filings?
NOVAVAX INC (NVAX) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on June 23, 2026.
What is NVAX's SEC CIK number?
NOVAVAX INC (NVAX)'s SEC Central Index Key (CIK) is 1000694. EDGAR lists every NVAX filing under that number.
Ask anything about NVAX
The research agent reads NVAX's filings, financials, insider trades and 13F holders, then answers with sources.